Skip to main content

Drug Interactions between methylnaltrexone and momelotinib

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

methylnaltrexone momelotinib

Applies to: methylnaltrexone and momelotinib

Consumer information for this interaction is not currently available.

MONITOR: Coadministration of momelotinib may increase the plasma concentrations of substrates of the organic cation 1 (OCT1) or multidrug toxin extrusion 1 (MATE1) transporters. Based on in vitro data, at clinically relevant concentrations, momelotinib is an inhibitor of OCT1 and its active metabolite, M21, may inhibit MATE1. However, clinical data are not available.

MANAGEMENT: Caution is advised if momelotinib is administered with sensitive substrates of OCT1 and/or MATE1. Patients should be monitored for the development of adverse effects. Dosage adjustments as well as clinical and laboratory monitoring should be considered whenever momelotinib is added to or withdrawn from therapy with these drugs. Individual product labeling for the coadministered drug may also be consulted for specific guidance.

Drug and food/lifestyle interactions

Moderate

methylnaltrexone food/lifestyle

Applies to: methylnaltrexone

Food may reduce the absorption of methylnaltrexone when taken orally, which may lead to lower blood levels of the medication and possibly reduced effectiveness. You should take oral preparations of methylnaltrexone on an empty stomach at least 30 minutes before your first meal of the day.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer